Skip to main content

Table 1 General and laboratory characteristics and drug history of the study population according to PLR quartiles

From: The association between platelet-to-lymphocyte ratio with mortality among patients suffering from acute decompensated heart failure

Variables Total PLR quartiles P
(n = 405) Q1
(PLR ≤ 118)
(n = 100)
Q2
(119 < PLR < 198)
(n = 103)
Q3
(198 ≤ PLR < 268)
(n = 101)
Q4
(PLR ≥ 268)
(n = 101)
Age(years) 65.9 ± 13.49 65.3 ± 13.15 66.5 ± 12.8 65.7 ± 12.91 66.25 ± 15.13 0.913
Males (%) 274 (67.7) 72 (72) 68 (66) 64 (63.4) 70 (69.3) 0.580
BMI(kg/m2) 26.85 ± 6.2 26.45 ± 6.9 27.49 ± 7.2 27.32 ± 6 26.32 ± 3.9 0.417
Heart rate (beats per minute) 85.28 ± 19.5 83.64 ± 20.3 86.81 ± 19.2 85.22 ± 18.7 85.41 ± 19.8 0.722
Ischemic heart disease (%) 358 (88.4) 89 (89) 90 (87.4) 89 (88.1) 90 (89.1) 0.978
Diabetes mellitus (%) 170 (42) 42 (42) 38 (36.9) 50 (49.5) 40 (39.6) 0.299
Hypertension (%) 194 (47.9) 47 (47) 51 (49.5) 50 (49.5) 46 (45.5) 0.926
Stroke (%) 18 (4.4) 4 (4) 5 (4.9) 4 (4) 5 (5) 0.977
Kidney diseases (%) 179 (44.2) 44 (44) 47 (45.6) 46 (45.5) 42 (41.6) 0.932
COPD (%) 142 (35.1) 41 (41)d 35 (34) 45 (44.6) 21 (20.8) 0.002
Smoking status (%) 152 (37.5) 38 (38) 36 (35) 37 (36.6) 41 (40.6) 0.864
Systolic blood pressure (mmHg) 121.01 ± 26.9 122.79 ± 26.9 121.01 ± 23.8 119.58 ± 24.2 120.68 ± 25.5 0.839
Diastolic blood pressure (mmHg) 75.67 ± 15.68 76.26 ± 16.6 75.54 ± 15.2 75.76 ± 14.1 75.14 ± 16.8 0.967
Left ventricular ejection fraction (%)       
 < 30 299 (73.8) 73 (73) 70 (68) 78 (77.2) 78 (77.2) 0.391
 30–40 61 (15.1) 18 (18) 17 (16.5) 12 (11.9) 14 (13.9)  
 40–50 27 (6.7) 3 (3) 9 (8.7) 9 (8.9) 6 (5.9)  
 > 50 18 (4.4) 6 (6) 7 (6.8) 2 (2) 3 (3)  
Hemoglobin (g/dl) 13.59 ± 3 14.27 ± 3b 13.79 ± 2.3 13.08 ± 3.5 13.23 ± 3 0.021
WBC (106/l) 5.4 ± 3.1 8.1 ± 3.7a,b,c 5.8 ± 2.9 4.1 ± 2.1 3.4 ± 0.6 < 0.001
Neutrophils (%) 68 ± 12.3 60.8 ± 14a,b,c 68.4 ± 10.6 66.8 ± 11.1 76 ± 8.1 < 0.001
Lymphocytes (%) 22 ± 9.5 28.1 ± 10.3a,b,c 23 ± 9.2 22 ± 6.9 15.1 ± 6.3 < 0.001
Platelets (109/l) 190.45 ± 68.9 160.23 ± 65.6b,c 175.28 ± 49.4 198.32 ± 59.9 227.97 ± 78.8 < 0.001
Sodium (mEq/l) 136.07 ± 4.8 137.42 ± 7b,c 136.5 ± 2.9 135.6 ± 3.8 134.76 ± 4.4 0.001
Potassium (mEq/l) 3.97 ± 0.5 3.98 ± 0.5 3.93 ± 0.5 3.97 ± 0.5 4.01 ± 0.5 0.762
Blood urea nitrogen (mg/dl) 83.36 ± 52.2 82.61 ± 60.9 84.22 ± 45.8 80.41 ± 48.8 86.2 ± 52.9 0.881
Creatinine (mg/dl) 1.56 ± 1.2 1.42 ± 0.7 1.50 ± 0.5 1.47 ± 0.7 1.84 ± 2.2 0.077
Drug history       
 Pre-admission       
  Beta blocker (%) 158 (39) 44 (44) 40 (38.8) 34 (33.7) 40 (39.6) 0.517
  ACEIs/ARBs (%) 200 (49.4) 47 (47) 46 (44.7) 54 (53.5) 53 (52.5) 0.531
  Diuretics (%) 271 (66.9) 62 (62) 72 (69.9) 72 (71.3) 65 (64.4) 0.444
  Statins (%) 205 (50.6) 53 (53) 48 (46.6) 55 (54.5) 49 (48.5) 0.645
  Oral anti-coagulants (%) 108 (26.7) 23 (23) 31 (30.1) 30 (29.7) 24 (23.8) 0.528
 Discharge       
  Beta blocker (%) 273 (67.4) 67 (67) 72 (69.9) 68 (67.3) 66 (65.3) 0.920
  ACEIs/ARBs (%) 192 (47.4) 49 (49) 50 (48.5) 49 (48.5) 44 (43.6) 0.849
  Diuretics (%) 326 (80.5) 82 (82) 87 (84.5) 78 (77.2) 79 (78.2) 0.532
  Oral anti-coagulants (%) 113 (27.9) 20 (20) 29 (28.2) 37 (36.6) 27 (26.7) 0.072
  1. PLR platelet to lymphocyte ratio, BMI body mass index, COPD chronic obstructive pulmonary disease, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, WBC white blood cells
  2. aP < 0.05 compared with quartile 2 resulted from post hoc Bonferroni test
  3. bP < 0.05 compared with quartile 3 resulted from post hoc Bonferroni test
  4. cP < 0.05 compared with quartile 4 resulted from post hoc Bonferroni test
  5. dP < 0.05 compared with quartile 4 resulted from post hoc test with Bonferroni correction